



# proCardio2022

THE GLOBAL CARDIAC  
BIOMARKER FORUM

#proCardioForum



12th International Symposium, 13–14<sup>th</sup> October, 2022

Hilton Hotel Munich Park, Munich, Germany

Each talk includes 5–10' Q&A; additional 20' for all talks follows at the end of each session.

## 13<sup>th</sup> October

**08:15–08:30 Welcome and introduction**  
James Januzzi (Boston, MA, US), Olivier Gilliéron (Roche Diagnostics) and Carolyn Lam (Singapore)

### Session 1: Basic science

*Chairs: Robert Christenson (Baltimore, MD, US); Gerard Pasterkamp (Utrecht, Netherlands)*

- 08:30–08:50 Kinetics of cTnT versus cTnI: An update on their similarities and differences**  
Alma Mingels (Maastricht, Netherlands)
- 08:50–09:10 Proteomic profiles and mechanistic pathways of progression to heart failure**  
Jasper Tromp (Singapore)
- 09:10–09:30 Pathophysiological evidence of biomarker relevance to cardiac amyloidosis**  
Giuseppe Vergaro (Pisa, Italy)
- 09:30–09:50 Biomarkers in hypertrophic cardiomyopathy, recent progress and future challenges**  
Caroline Coats (Glasgow, UK)
- 09:50–10:10 Development of an IGFBP7 antibody as a heart failure treatment**  
Peter Liu (Ontario, Canada)
- 10:10–10:30 Q&A**

Coffee break

### Session 2: Prevention

*Chairs: Shelley Zieroth (Manitoba, Canada); Rudolf de Boer (Groningen, Netherlands)*

- 10:45–11:10 Population-wide biomarker screening for cardiovascular disease: Pros and cons?**  
Cynthia Papendick (Adelaide, Australia)
- 11:10–11:35 Hip attack - prevention of MACE after hip fracture**  
Flavia Borges (Ontario, Canada)
- 11:35–12:00 Cardiooncology**  
Ninian Lang (Glasgow, UK)
- 12:00–12:25 Value of biomarkers in prevention of cardiorenal complications in type 2 diabetes**  
Muthiah Vaduganathan (Boston, MA, US)
- 12:25–12:45 Q&A**

Lunch

### Session 3: Diagnosis

*Chairs: Cynthia Papendick (Adelaide, Australia); Rick Body (Manchester, UK)*

- 13:45–14:10 Diagnosis of type 1 vs type 2 myocardial infarction**  
Lori Daniels (San Diego, CA, US)
- 14:10–14:35 How to triage patients with suspected ACS: Reducing the observe zone**  
Nicholas Mills (Edinburgh UK)
- 14:35–15:00 Challenges in the use of NT-proBNP in the diagnosis of heart failure with preserved ejection fraction**  
Muthiah Vaduganathan (Boston, MA, US)
- 15:00–15:25 Biomarker insights across the ejection fraction spectrum**  
Jonathan Cunningham (Boston, MA, US)
- 15:25–15:45 Q&A**

Coffee break

### Session 4: Risk stratification

*Chairs: Paulus Kirchhof (Hamburg, Germany); Allan Jaffe (Rochester, MN, US)*

- 16:00–16:25 Predictive models for prevalent and recurrent atrial fibrillation (BMP-10)**  
Larissa Fabritz (Hamburg, Germany)
- 16:25–16:50 Multiplex biomarkers: How do they compare to single markers**  
Agneta Siegbahn (Uppsala, Sweden)
- 16:50–17:15 Heart-brain interactions in cardiac arrhythmia: Findings from the Swiss AF study**  
Stefanie Aeschbacher (Basel, Switzerland)
- 17:15–17:40 Risk stratification of acute myocardial infarction using a single hs-cTnT measurement**  
Yader Sandoval (Minneapolis, MN, US)
- 17:40–18:00 Q&A**

Off site Dinner: Augustiner Schützengarten

**18:00–18:15 Conclusion and wrapping up of the day**

## 14<sup>th</sup> October

### Session 5: Therapy

*Chairs: Evangelos Giannitsis (Heidelberg, Germany); Faïez Zannad (Paris, France)*

- 08:30–08:50 Individualised clinical approaches in heart failure with preserved ejection fraction**  
Carolyn Lam (Singapore)
- 08:50–09:10 Sex-specific considerations in drug and device therapy of cardiac arrhythmias**  
Ileana Piña (Detroit, MI, US)
- 09:10–09:30 Heart failure with preserved ejection fraction – a changing landscape**  
Antoni Bayes-Genis (Barcelona, Spain)
- 09:30–09:50 Can we improve clinical reporting of lipid fractions to properly treat LDL-C and Lp(a) in high-risk patients?**  
Christie Ballantyne (Houston, TX, US)
- 09:50–10:10 Assessment and monitoring of congestion in heart failure**  
Alexandre Mebazaa (Paris, France)
- 10:10–10:30 Q&A**

Coffee break

### Session 6: Innovation

*Chairs: David Morrow (Boston, MA, US); Christopher Baugh (Boston, MA, US)*

- 10:45–11:00 Innovative biomarker development**  
Winnie Chua (Birmingham, UK)
- 11:00–11:15 Digital decision support tool and disease management solutions**  
Rick Pleijhuis (Groningen, Netherlands)
- 11:15–11:30 cTnI and cTnT: Different biology, same diagnostic performance?**  
Christian Mueller (Basel, Switzerland)
- 11:30–11:45 Proteomic analysis – sex differences in heart failure**  
Emily Lau (Boston, MA, US)
- 11:45–12:00 Blood-based biomarkers to search for atrial fibrillation in high-risk asymptomatic individuals and cryptogenic stroke patients**  
Joan Montaner (Seville, Spain)
- 12:00–12:15 Q&A**

**12:15–12:30 Conclusion**

The program ends at 12:30pm on 14<sup>th</sup> Oct to allow for Advisory Boards on different topics to take place in the afternoon.